The IBC establishes, monitors and enforces policies and procedures which meet or exceed applicable norms or regulations for biohazardous materials and/or recombinant DNA, including gene transfer clinical trials. Any use of biohazardous materials and/or recombinant DNA must be reviewed and approved by the IBC (or the Biological Safety Officer operating within guidelines established by the IBC).
The IBC has the authority to impose disciplinary measures in cases where there is
Principal investigators, follow these instructions for gene transfer clinical trial submission to UC San Diego's Institutional Biosafety Committee.
National Institutes of Health (NIH) Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules is the definitive reference for rDNA research in the United States and has been adopted by UC San Diego.
It is the principal investigator's responsibility to ensure ALL regulations and requirements are met.
Contact EH&S Biosafety with any questions.